Publication: Tropomyosin 2 exerts anti-tumor effects in lung adenocarcinoma and is a novel prognostic biomarker
Authors
Duan, Peng ; Cui, Jing ; Li, Hongyan ; Yuan, Lei
item.page.secondaryauthor
item.page.director
Publisher
Universidad de Murcia, Departamento de Biologia Celular e Histiologia
publication.page.editor
publication.page.department
DOI
https://doi.org/10.14670/HH-18-514
item.page.type
info:eu-repo/semantics/article
Description
Abstract
Background. Tropomyosin 2 (TPM2), a
member of the actin filament binding protein family,
plays distinct roles in the progression of different cancer
types. Until now, there has been no study reporting
TPM2 expression nor its function in lung adenocarcinoma (LUAD).
Methods. In the present study, we examined the
expression profile of TPM2 by immunohistochemistry
(IHC). The clinical significance of TPM2 was assessed
by univariate and multivariate analyses. Function of
TPM2 in LUAD was evaluated by knockdown and
overexpression strategies in three LUAD cell lines,
followed by proliferation and invasion assays.
Xenografts were conducted in nude mice to further
validate the tumor-related role of TPM2.
Results. Our results showed that TPM2 was
downregulated in LUAD specimens and the low
expression of TPM2 was associated with poor outcomes
of LUAD patients. Overexpressing TPM2 inhibited cell
proliferation and invasion of LUAD cell lines, while
silencing TPM2 exerted the opposite effects. The effects
of TPM2 in LUAD were further confirmed by xenograft
assays.
Conclusions. Our results indicated that TPM2
exerted an anti-oncogenic role in LUAD via inhibiting
tumor progression, thus providing a novel dire
publication.page.subject
Citation
Histology and Histopathology Vol. 38, nº6 (2023)
item.page.embargo
Ir a EstadÃsticas
Este Ãtem está sujeto a una licencia Creative Commons. http://creativecommons.org/licenses/by-nc-nd/4.0/